PT-141

PT-141 (Bremelanotide Acetate) – Premium Libido Enhancement Peptide for Research | Boost Sexual Desire & Arousal with Central Melanocortin Activation

Ignite passion and elevate intimate wellness with PT-141 Bremelanotide Acetate, the advanced synthetic peptide engineered for cutting-edge research into sexual arousal, desire pathways, and melanocortin receptor modulation. This powerful research compound offers a unique central nervous system approach to studying libido enhancement, making it a standout choice for laboratories exploring alternatives to traditional vascular-focused treatments.

Premium Product Overview

PT-141 (Bremelanotide), also known as Bremelanotide Acetate, is a cyclic heptapeptide derived as a metabolite of Melanotan II. It functions as a selective melanocortin receptor agonist, primarily targeting MC3R and MC4R in the brain to stimulate sexual desire and arousal without relying on hormonal changes or peripheral blood flow mechanisms.

Supplied in the stable acetate salt form for excellent solubility and reconstitution, PT-141 features a refined structure optimized for central effects. With a molecular formula of C₅₀H₆₈N₁₄O₁₀ (free base) or C₅₂H₇₂N₁₄O₁₂ (acetate) and a molecular weight of approximately 1025.2 Da (free base) / 1085.2 Da (acetate), this high-purity lyophilized peptide is ideal for precise experimental applications in sexual function and wellness research.

Available in convenient 10mg vials (or higher concentrations depending on supplier), PT-141 peptide is provided at ≥99% purity (HPLC verified) for reliable research outcomes.

Key Research Benefits of PT-141 (Bremelanotide)

• Enhanced Sexual Desire & Arousal: Activates melanocortin pathways in the hypothalamus to increase libido and sexual motivation in both male and female research models—ideal for studies on hypoactive sexual desire disorder (HSDD) and related conditions.
• Improved Sexual Function: Promotes stronger erectile responses and overall gratification, with effects often noticeable within 45–60 minutes and lasting several hours in studied contexts. Offers potential as a non-hormonal, centrally acting alternative to PDE5 inhibitors.
• On-Demand Libido Support: Designed for as-needed use, supporting investigations into rapid-onset arousal without continuous daily administration.
• Minimal Pigmentation Effects: Unlike its parent compound Melanotan II, PT-141 focuses primarily on sexual pathways with reduced impact on skin tanning, allowing cleaner research into libido-specific mechanisms.

Researchers often refer to PT-141 as the “Arousal Peptide” or “Libido Peptide” for its targeted ability to reignite desire and confidence in experimental settings.

Incorporate these naturally for better search engine performance on pages about PT-141 libido research, Bremelanotide for sexual wellness, and premium research peptides for arousal.

Quality Assurance & Usage in Research

Sourced exclusively for laboratory research, PT-141 Bremelanotide Acetate reconstitutes easily with bacteriostatic water. Its cyclic design ensures strong receptor affinity and stability, making it a preferred tool for melanocortin pathway and sexual function studies.

Common Research Protocols (for reference only): Subcutaneous administration in studied models typically uses 1.75–2 mg, injected 45–60 minutes before anticipated activity. Start low and titrate to minimize observations like nausea. Do not exceed one dose per 24 hours or eight doses per month in protocols. Store lyophilized vials at -20°C and reconstituted solutions refrigerated for maximum efficacy.

Important Research Considerations

While PT-141 (Bremelanotide) demonstrates promising effects on sexual desire and function in controlled research, it is a potent peptide intended strictly for laboratory use. It is FDA-approved in a specific formulation (Vyleesi) for HSDD in premenopausal women but remains a research chemical in peptide form—not evaluated or approved for general human cosmetic, therapeutic, or personal applications in many contexts. Common observations include nausea (most frequent, up to 40%), flushing, headache, injection site reactions, and transient blood pressure increases. Effects are usually mild and transient; long-term safety data continues to evolve. Prioritize proper protocols and consult qualified professionals for any application beyond strict lab research.

Elevate your peptide research portfolio with PT-141 Bremelanotide Acetate—where innovative science unlocks insights into desire, arousal, and intimate vitality. Experience the potential of targeted melanocortin activation in one advanced research peptide.

For research purposes only. Not for human consumption, diagnostic, or therapeutic use. Always comply with local laws and institutional protocols.